TALECRIS VISION
CORPORATE SITES
Talecris Canada
Talecris Europe
Talecris United States
View All
PRODUCT SITES
Alpha-1 Antitrypsin Deficiency
(Prolastin/Prolastina)
Immune Globulin Intravenous
Therapy
(IGIV) (Gamunex)
Antihemophilic Factor VIII
(Koāte-DVI)
Antithrombin III (AT III)
(Thrombate)
Human Albumin Products
(Plasbumin / Plasmanate)
Hyperimmune Globulin Therapy
(Hypermunes)
View All
PROGRAMS & SERVICES
Gamunex Connexions
Gamunex Direct
Prolastin Direct
Contract Manufacturing Services
Talecris Plasma Resources
View All
CONTACT TALECRIS
Home
About Talecris
Therapeutic Areas
Research & Development
Donor to Patient
Media Center
Talecris Careers
Media Center Overview
Press Releases
Press Releases Archive
News Features
The History of Talecris
Talecris Leadership
Talecris Media Contact Information
Media Center Overview
Press Releases
Subscribe to the Talecris Press Release RSS feed (W3C validated)
June 09, 2009
Talecris Biotherapeutics Receives Orphan Drug Designation for Plasmin (Human) to Treat Acute Peripheral Arterial Occlusion
June 04, 2009
Alpha-1 Foundation Announces the Million Dollar Match Program Made Possible by a Talecris Biotherapeutics Grant
May 28, 2009
Talecris Responds to U.S. Federal Trade Commission Filing of Complaint to Challenge Proposed CSL Transaction
May 18, 2009
Talecris Presents New Data from Phase III Studies of a More Concentrated Formulation of Prolastin® to Treat AAT Deficiency
April 23, 2009
New Publication of Landmark Study Demonstrates Gamunex® Improves Health-Related Quality of Life in Patients with CIDP
See how Talecris is being
recognized for innovation and commitment
.
Contact Talecris
Glossary
Site Map
General Conditions of Use
Privacy Statement
California Compliance
© 2009 Talecris Biotherapeutics
